Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Ponce Therapeutics, Inc. ("Ponce"), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeting aging-associated skin disorders. The Company has secured laboratory space in Houston, TX, and has hired its first scientists for executing their R & D plan targeting the elimination of p16-expressing cells in the skin. The cell proliferation inhibitor, p16, is...
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. Bellicum worked diligently with the F...
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech
Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T® product candidate that incorporates the company’s iMC activation and CaspaCIDe® safety switch tech...
Bellicum Pharmaceuticals said on Monday the U.S. Food and Drug Administration had placed a clinical hold on patient enrollment and dosing in an ongoing early-stage trial of its treatment for patients with pancreatic or prostate cancer. The company said the FDA's action follows the death of a pancreatic cancer patient in the trial that the company reported to the agency.